Change in Antibodies to SARS-CoV-2 Among Health Care Personnel in Nashville, Tennessee | Infectious Diseases | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Change in Antibodies to SARS-CoV-2 Over 60 Days Among Health Care Personnel in Nashville, Tennessee

Educational Objective
To understand what changes occur in antibodies to SARS-CoV-2 over a 60 day period
1 Credit CME

Declines in immunoglobulin antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among patients with symptomatic or asymptomatic infections have been documented.1,2 We assessed the duration of antibody response to SARS-CoV-2 infection in health care personnel, who may be at particular risk if antibody levels decline.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Manish M. Patel, MD, Influenza Division, Centers for Disease Control and Prevention, 1600 Clifton Rd, MS H24-7, Atlanta, GA 30329 (mpatel@cdc.gov).

Accepted for Publication: September 4, 2020.

Published Online: September 17, 2020. doi:10.1001/jama.2020.18796

Author Contributions: Drs Patel and Self had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Patel, Thornburg, Stubblefield, Talbot, Feldstein, Self.

Acquisition, analysis, or interpretation of data: Patel, Thornburg, Stubblefield, Talbot, Coughlin, Self.

Drafting of the manuscript: Patel, Self.

Critical revision of the manuscript for important intellectual content: Thornburg, Stubblefield, Talbot, Coughlin, Feldstein, Self.

Statistical analysis: Patel, Coughlin.

Obtained funding: Patel, Self.

Administrative, technical, or material support: Stubblefield, Talbot, Coughlin, Feldstein, Self.

Supervision: Patel, Thornburg, Self.

Conflict of Interest Disclosures: Dr Coughlin reported US Patent 7,728,110B2, an isolated human monoclonal antibody that specifically binds to SARS-CoV S protein. No other disclosures were reported.

Funding/Support: This work was funded by Centers for Disease Control and Prevention contract 75D30120C07637 (Dr Self).

Role of the Funder/Sponsor: The Centers for Disease Control and Prevention was involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: The findings and conclusions of this report are those of the authors and do not necessarily reflect the official position of the Centers for Disease Control and Prevention.

References
1.
Ibarrondo  FJ , Fulcher  JA , Goodman-Meza  D ,  et al.  Rapid decay of Anti-SARS-CoV-2 antibodies in persons with mild Covid-19.   N Engl J Med. Published online July 21, 2020. doi:10.1056/NEJMc2025179 PubMedGoogle Scholar
2.
Long  QX , Tang  XJ , Shi  QL ,  et al.  Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections.   Nat Med. 2020;26(8):1200-1204. doi:10.1038/s41591-020-0965-6 PubMedGoogle ScholarCrossref
3.
Stubblefield  WB , Talbot  HK , Feldstein  L ,  et al; Influenza Vaccine Effectiveness in the Critically Ill (IVY) Investigators.  Seroprevalence of SARS-CoV-2 among frontline healthcare personnel during the first month of caring for COVID-19 patients–Nashville, Tennessee.   Clin Infect Dis. 2020;ciaa936. doi:10.1093/cid/ciaa936 PubMedGoogle Scholar
4.
Havers  FP , Reed  C , Lim  T ,  et al.  Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020.   JAMA Intern Med. Published online July 21, 2020. doi:10.1001/jamainternmed.2020.4130PubMedGoogle Scholar
5.
Premkumar  L , Segovia-Chumbez  B , Jadi  R ,  et al.  The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.   Sci Immunol. 2020;5(48):eabc8413. doi:10.1126/sciimmunol.abc8413PubMedGoogle Scholar
6.
Grifoni  A , Weiskopf  D , Ramirez  SI ,  et al.  Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.   Cell. 2020;181(7):1489-1501.e15. doi:10.1016/j.cell.2020.05.015PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close